A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Clinical trial NCT04657289 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04657289
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-14
- Primary completion
- 2027-02-04
- Enrollment
- 451
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.